HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caspase-mediated cleavage of X-ray repair cross-complementing group 4 promotes apoptosis by enhancing nuclear translocation of caspase-activated DNase.

Abstract
X-ray repair cross-complementing group 4 (XRCC4), a repair protein for DNA double-strand breaks, is cleaved by caspases during apoptosis. In this study, we examined the role of XRCC4 in apoptosis. Cell lines, derived from XRCC4-deficient M10 mouse lymphoma cells and stably expressing wild-type XRCC4 or caspase-resistant XRCC4, were established and treated with staurosporine (STS) to induce apoptosis. In STS-induced apoptosis, expression of wild-type, but not caspase-resistant, XRCC4 in XRCC4-deficient cells enhanced oligonucleosomal DNA fragmentation and the appearance of TUNEL-positive cells by promoting nuclear translocation of caspase-activated DNase (CAD), a major nuclease for oligonucleosomal DNA fragmentation. CAD activity is reportedly regulated by the ratio of two inhibitor of CAD (ICAD) splice variants, ICAD-L and ICAD-S mRNA, which, respectively, produce proteins with and without the ability to transport CAD into the nucleus. The XRCC4-dependent promotion of nuclear import of CAD in STS-treated cells was associated with reduction of ICAD-S mRNA and protein, and enhancement of phosphorylation and nuclear import of serine/arginine-rich splicing factor (SRSF) 1. These XRCC4-dependent, apoptosis-enhancing effects were canceled by depletion of SRSF1 or SR protein kinase (SRPK) 1. In addition, overexpression of SRSF1 in XRCC4-deficient cells restored the normal level of apoptosis, suggesting that SRSF1 functions downstream of XRCC4 in activating CAD. This XRCC4-dependent, SRPK1/SRSF1-mediated regulatory mechanism was conserved in apoptosis in Jurkat human leukemia cells triggered by STS, and by two widely used anti-cancer agents, Paclitaxel and Vincristine. These data imply that the level of XRCC4 expression could be used to predict the effects of apoptosis-inducing drugs in cancer treatment.
AuthorsYumi Sunatani, Radhika Pankaj Kamdar, Mukesh Kumar Sharma, Tadashi Matsui, Ryo Sakasai, Mitsumasa Hashimoto, Yasuhito Ishigaki, Yoshihisa Matsumoto, Kuniyoshi Iwabuchi
JournalExperimental cell research (Exp Cell Res) Vol. 362 Issue 2 Pg. 450-460 (01 15 2018) ISSN: 1090-2422 [Electronic] United States
PMID29233683 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2017 Elsevier Inc. All rights reserved.
Chemical References
  • DNA-Binding Proteins
  • Srsf1 protein, mouse
  • XRCC4 protein, mouse
  • Serine-Arginine Splicing Factors
  • Vincristine
  • Srpk1 protein, mouse
  • Protein Serine-Threonine Kinases
  • Deoxyribonucleases
  • caspase-activated deoxyribonuclease
  • Staurosporine
  • Paclitaxel
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Nucleus (genetics)
  • DNA Fragmentation (drug effects)
  • DNA Repair (genetics)
  • DNA-Binding Proteins (genetics)
  • Deoxyribonucleases (genetics)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Jurkat Cells
  • Mice
  • Neoplasms (drug therapy, genetics, pathology)
  • Paclitaxel (pharmacology)
  • Protein Serine-Threonine Kinases (genetics)
  • Serine-Arginine Splicing Factors (genetics)
  • Signal Transduction (drug effects)
  • Staurosporine (pharmacology)
  • Vincristine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: